Why Farbe Firma is the Top Manufacturer of Caffeine Citrate Injection
- Maulik Sudani
- 2 days ago
- 7 min read
Last Updated: June 17, 2026
TL;DR: Caffeine Citrate Injection — a sterile, clear, colourless, preservative-free aqueous solution of caffeine citrate, a methylxanthine central-nervous-system and respiratory stimulant, supplied commonly as 20 mg/mL caffeine citrate (equivalent to 10 mg/mL caffeine base) in a 60 mg/3 mL single-dose vial for intravenous infusion (and oral use) — is the standard hospital agent for the treatment of apnoea of prematurity in neonates. Because the patient is a premature newborn dosed at exact, weight-based, sub-gram amounts, each vial must deliver a precise, sterile, particulate-free, preservative-free dose at the labelled concentration with the caffeine base equivalence stated unambiguously, with the assay, the citrate ratio, the impurity and degradation profile, solution pH, fill volume, very low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Caffeine Citrate Injection at our Gujarat, India facility and supplies it to neonatal intensive care, hospital pharmacy and paediatric services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Methylxanthine central-nervous-system and respiratory stimulant — Caffeine Citrate Injection is given intravenously (and orally) for the treatment of apnoea of prematurity in neonates, typically as a loading dose followed by once-daily maintenance, with caffeine base equivalence (10 mg caffeine base = 20 mg caffeine citrate) stated to prevent dosing error.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated preservative-free solution compounding and vial filling lines, control of the stability-indicating assay, the 2:1 caffeine-to-citric-acid ratio, the impurity profile, solution pH, fill volume, very low particulate and endotoxin for a neonatal parenteral, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready vial packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Caffeine Citrate Injection Demands a Premium Manufacturer
Caffeine Citrate Injection holds an essential, life-supporting place in neonatal intensive care across every market. It is the methylxanthine respiratory stimulant that neonatologists rely on to treat apnoea of prematurity — the recurrent pauses in breathing common in premature infants — by stimulating the central respiratory drive, increasing sensitivity to carbon dioxide and improving diaphragmatic function. Caffeine citrate has become the agent of choice in this setting because of its wide therapeutic margin, predictable handling and once-daily maintenance dosing. In this most vulnerable of patient populations the dose delivered from each vial must be exact, sterile, particulate-free, preservative-free and reliably the same from unit to unit, because safe and effective respiratory support depends on a precise, reproducible, weight-based dose delivered in a small volume to a premature newborn.
That clinical reality places exceptional demands on the manufacturer. The product is a low-strength aqueous solution in which caffeine and citric acid (with sodium citrate) are held in a defined ratio, and which must remain a clear, colourless, particulate-free solution within a narrow pH window throughout shelf life. Because it is given to neonates, the formulation is preservative-free, and endotoxin and particulate limits are held to the most stringent end of the parenteral range. The assay of caffeine must be exact and must be expressed against the caffeine base so that the 10 mg base / 20 mg citrate equivalence is unmistakable on every label and certificate; the impurity and degradation profile must stay within tight limits; the pH and the deliverable volume must be controlled so each vial gives the labelled dose at the labelled concentration. Choosing a Caffeine Citrate Injection manufacturer that treats preservative-free aseptic control, ultra-low endotoxin and particulate control, the stability-indicating assay, the base-versus-salt labelling and container-closure integrity as core engineering disciplines is what protects the newborn at the point of care.
What Sets a World-Class Caffeine Citrate Injection Manufacturer Apart
A world-class manufacturer of Caffeine Citrate Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of caffeine — expressed against the caffeine base with control of the caffeine-to-citrate ratio and of related substances and degradation products by HPLC — that a neonatal parenteral demands, a robust, validated sterilisation and preservative-free fill process that protects sterility and the very low endotoxin burden required for newborns, and tender-ready dossier support for a hospital-formulary neonatal product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade caffeine and citric acid / sodium citrate sourced from qualified, audited makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend both the assay and the safety of a neonatal dose. The bulk solution is compounded in water-for-injection so that caffeine and citric acid are present in the defined ratio that fixes the labelled caffeine-base concentration and the target pH, without any antimicrobial preservative, sterile-filtered through 0.22 µm membrane, and filled into single-dose vials under ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where qualified for this thermally stable molecule, otherwise full aseptic processing — locked in the master batch record. Filled vials are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of caffeine by validated HPLC, the caffeine-to-citrate ratio, the related-substance profile, solution pH, deliverable volume, visible and sub-visible particulate matter, and that endotoxin is held to the stringent limit appropriate to a neonatal intravenous product. Because the patient is a premature newborn, deliverable-volume accuracy, ultra-low endotoxin and the unambiguous base-versus-salt statement are confirmed and documented with particular rigour.
Quality Systems Behind Every Caffeine Citrate Injection
Every Farbe Firma Caffeine Citrate Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of caffeine against pharmacopoeial reference standards expressed as caffeine base, verification of the caffeine-to-citric-acid ratio, control of related substances and degradation products by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL at the neonatal-appropriate limit, sterility by membrane filtration, and container-closure integrity for the single-dose vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated vial-filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because caffeine citrate is given to premature newborns and the assay, base-equivalence, pH, particulate and endotoxin burden of the solution drive both efficacy and safety, we treat the stability-indicating HPLC assay expressed as caffeine base, the caffeine-to-citrate ratio, the endotoxin level, the solution pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and in-use stability is established to support neonatal infusion preparation.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Caffeine Citrate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a focused neonatal and paediatric small-volume parenteral portfolio alongside critical-care and supportive-care categories. For Caffeine Citrate Injection specifically, we supply the 60 mg/3 mL single-dose vial of preservative-free sterile solution — 20 mg/mL caffeine citrate, equivalent to 10 mg/mL caffeine base — under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, base-equivalence, endotoxin, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Caffeine Citrate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development expressed as caffeine base, the caffeine-to-citrate ratio, related-substance and degradation control, preservative-free aseptic and terminal-sterilisation strategy, ultra-low endotoxin and particulate control for neonates, base-versus-salt labelling that prevents dosing error, deliverable-volume accuracy, container-closure integrity and shelf-life choices in real detail. For a neonatal respiratory stimulant where dose accuracy, base equivalence, endotoxin control and a preservative-free formulation directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Caffeine Citrate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Caffeine Citrate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, dedicated preservative-free solution compounding and vial filling lines, validated sterilisation, qualified water-for-injection systems, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Caffeine Citrate Injection do you supply?
Our standard presentation is the 60 mg/3 mL single-dose vial of preservative-free sterile solution — 20 mg/mL caffeine citrate, equivalent to 10 mg/mL caffeine base — for intravenous infusion and oral use. Custom strengths, fill configurations, vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Caffeine Citrate Injection mainly used for?
Caffeine Citrate Injection is used for the treatment of apnoea of prematurity in neonates. It is a methylxanthine central-nervous-system and respiratory stimulant given as a loading dose followed by once-daily maintenance; Farbe Firma verifies the assay expressed as caffeine base, the caffeine-to-citrate ratio, clarity, deliverable volume, pH, particulate matter and endotoxin at release so each vial delivers a precise, reproducible neonatal dose.
Can Farbe Firma support country-specific registrations for Caffeine Citrate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Caffeine Citrate Injection contract manufacturing?
MOQs vary by strength, vial size, sterilisation route, label complexity and dossier requirements. For our neonatal small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments